利妥昔单抗治疗类风湿关节炎相关外周溃疡性角膜炎的疗效与安全性
该病例系列纳入7例类风湿关节炎相关外周溃疡性角膜炎患者,接受利妥昔单抗1000 mg第1天和第15天给药至少一次。中位随访29.8个月后,所有患者角膜炎症得到控制,1例复发,71%患者关节应答良好,未观察到利妥昔单抗相关严重不良事件。
要点
- 利妥昔单抗可有效控制类风湿关节炎相关外周溃疡性角膜炎的角膜炎症。
- 中位随访29.8个月,7例中1例在单次输注后8个月复发。
- 71%患者关节应答良好,未观察到利妥昔单抗相关严重不良事件。
核心结论
- 利妥昔单抗似乎是治疗类风湿关节炎相关外周溃疡性角膜炎有效且安全的选择。
研究设计与样本
- 病例系列研究,纳入2014年2月至2020年6月期间转诊至本院风湿科和眼科的类风湿关节炎相关外周溃疡性角膜炎患者。
- 患者接受利妥昔单抗1000 mg第1天和第15天给药至少一次,回顾性收集人口学及临床和生物学特征。
- 共纳入7例患者(3男4女,中位年龄58岁)。
主要发现
- 除1例外,其余患者均为长病程类风湿关节炎,中位病程13.9年(IQR 0-30.2)。
- 7例中6例类风湿关节炎为侵蚀性,所有患者类风湿因子阳性,6例抗瓜氨酸化肽抗体阳性。
- 3例患者外周溃疡性角膜炎并发角膜穿孔并需手术。
- 中位随访29.8个月(IQR 5-75)后,所有患者角膜炎症得到控制,1例在单次利妥昔单抗输注后8个月复发。
- 71%患者关节应答良好,无患者出现其他类风湿血管炎表现,未观察到利妥昔单抗相关严重不良事件。
临床怎么用
- 对于类风湿关节炎相关外周溃疡性角膜炎患者,可考虑使用利妥昔单抗1000 mg第1天和第15天方案治疗。
- 治疗期间需关注角膜炎症控制情况,并监测外周溃疡性角膜炎复发。
局限性
- 本研究为回顾性病例系列,样本量小(7例),缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Peripheral ulcerative keratitis (PUK) is a rare but severe ocular complication of rheumatoid arthritis (RA). It can be considered as an ocular manifestation of rheumatoid vasculitis (RV). Our case series aimed to evaluate the efficacy of rituximab (RTX) for PUK occurring in patients with RA. METHODS: Study population were patients with RA-associated PUK treated with RTX 1000 mg on days 1 and 15 at least once after the diagnosis. We identified patients referred to the rheumatology and ophthalmology departments of our hospital between February 2014 and June 2020. We also included patients referred by their specialist after being contacted through the Club Rhumatismes et Inflammation. Demographic data and clinical and biological features were retrospectively collected. RESULTS: We included seven patients (three men and four women, median age 58 years). All but one had a long-standing RA with a median disease duration of 13.9 years (IQR 0-30.2). RA was erosive in six out of seven patients. All patients had rheumatoid factors and anticitrullinated peptides antibodies were positive in six of them. PUK was complicated by corneal perforation in three patients and required surgery. After a median follow-up of 29.8 months (IQR 5-75), corneal inflammation was controlled in all patients. PUK recurred in one patient, 8 months after a single infusion of RTX. 71% of the patients presented a good articular response. No patient developed other manifestations of RV. No serious adverse event related to RTX was observed. CONCLUSION: RTX appears to be an efficient and safe therapeutic option in the treatment of RA-associated PUK.
引用
- Bonnet I, Rousseau A, Duraffour P, et al. Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis. RMD Open. 2021. PMID: 33510042. doi:10.1136/rmdopen-2020-001472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。